Feb. 6, 2024—CellaVision and Sysmex announced a strategic alliance agreement that expands their mutual commitment until 2038. Sysmex’s expertise in hematology combined with CellaVision’s advanced imaging solutions and AI-assisted cell classifications lay the groundwork for the continued innovation of state-of-the-art offerings, according to a joint press release from the companies.
“We are delighted to further strengthen our ties with Sysmex to continue the global adoption of advanced digital cell morphology solutions integrated with the leading cell counter offerings of Sysmex,” Simon Østergaard, president and CEO of CellaVision, said in the press release.